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Calcium channel blockers (CCBs) represent a chemically and pharmacologically diverse
group of agents that are widely used for the treatment of hypertension and angina. A small
number of retrospective, observational analyses have raised concern about a potential causal
link between CCB use and an increased risk for cancer development. Despite the absence of
cancer findings in extensive preclinical studies, it has been proposed that CCBs may work
differently in humans by interfering with apoptosis, leading to an increased potential for
abnormal cell proliferation and tumor growth. This biologic hypothesis has attracted
considerable attention in the medical community but has not been critically evaluated. An
analysis of the basic and clinical literature was conducted to examine biologic relationships
among cell Ca21 modulation, apoptosis, and cancer. In addition to a comprehensive review
of the cellular and animal data, the results of large observational studies were included in this
analysis. Results of this review demonstrated that the effects of CCBs on apoptosis are
complex as both increases and decreases in intracellular Ca21 have been linked to this form
of programmed cell death. Most studies show that an effect (either positive or negative) of
CCBs on apoptosis requires doses in the supra-pharmacologic range, and are therefore not
clinically relevant. Results of large and methodologically robust observational studies fail to
provide support for the hypothesis that CCB use is associated with an increased susceptibility
for cancer incidence. A comprehensive analysis of the basic and clinical evidence does not
support a causal relationship between the therapeutic use of CCBs and an increased incidence
of cancer development as a result of interfering with apoptosis. (J Am Coll Cardiol 1999;34:
1857–66) © 1999 by the American College of Cardiology
OVERVIEW
With the introduction of specific L-type calcium channel
blockers (CCBs) for the treatment of hypertension and
angina, the effects of these compounds on the development
and spread of cancer have been carefully investigated
over the past two decades. Results of these studies have
provided important insights into the biologic relationship
between cell calcium (Ca21) regulation and mechanisms
of proliferation. The objective of this review was to critically
evaluate the hypothesis that CCB use is associated with
increased carcinogenic potential by interfering with cellular
apoptosis, an important form of programmed cell death.
This analysis was based on a comprehensive review of
cellular, animal, and human evidence on this subject. At
the cellular level, the demonstrated effects of CCBs and
Ca21 on apoptosis are complex as both increases and
decreases in intracellular Ca21 can be linked to apoptosis.
Although CCBs inhibit apoptosis in certain nontrans-
formed cell lines at supra-pharmacologic concentrations,
a number of independent reports have shown that CCBs
promote apoptosis in transformed cell lines, leading to a
reduction in tumor development. Extensive preclinical ani-
mal studies have failed to demonstrate a link between
extended CCB use and increased rates of neoplasia or
developmental defects. The animal safety data are validated,
in turn, by an analysis of a number of large and method-
ologically sound clinical investigations. Thus, a critical
and objective review of the basic and clinical evidence does
not support the hypothesis that CCB use is associated
with an increased risk for cancer development as a result of
interfering with apoptosis.
DISCUSSION
Apoptosis: A complex biologic process. In the past
decade, considerable scientific attention has been directed
to the cellular regulation of apoptosis, a form of pro-
grammed cell death associated with embryogenesis and
tissue turnover. In biologic systems, apoptosis is a geneti-
cally regulated, energy-dependent process that effects cell
death and removal in an efficient manner (1). During animal
development, apoptosis is required for the efficient model-
ing and development of tissue derived from the early
blastocyst. Apoptosis is especially critical to the proper
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formation of the emerging central nervous system; during
development, as many as 50% of cells that form the nervous
system die before full maturation as a result of programmed
cell death. In the adult organism, the regulation of normal
tissue mass is controlled by a balanced production of growth
and death factors that regulate mitosis and apoptosis,
respectively.
As a mechanism of cell death, apoptosis is very distinct
from necrosis: whereas apoptosis is a deliberate process
modulated by specific genetic pathways, necrosis can be
considered accidental, as when a toxin blocks cellular
functions necessary for survival (2). Morphologically, the
cell undergoing apoptosis is characterized by a reduction in
cell volume, while the chromatin becomes pyknotic and
condensed into delineated fragments associated with the
nuclear envelope. Nuclear condensation during apoptosis
can be detected by microscopy approaches, especially con-
focal laser scanning microscopy. The nuclear chromatin in
the apoptotic cell then condenses, typically followed by a
loss of the nuclear membrane and fragmentation of the
nuclear DNA into discrete, 180 to 200-bp fragments (3).
When run on a gel, the fragments are distributed in a
periodic fashion, referred to as “DNA laddering.” The
DNA breaks associated with apoptosis can be visualized by
microscopy following terminal deoxynucleotide transferase-
mediated dUTP-biotin nick end labeling (TUNEL) and in
situ end labeling (4). TUNEL approaches are commonly
used in combination with other techniques (microscopy, gel
electrophoresis) to demonstrate apoptosis, because necrotic
cells have also been shown, at times, to stain with this
technique (5). In addition to DNA fragmentation, apoptosis
is characterized by condensation of the cytoplasm, elimina-
tion of microvilli, and cell-surface blebbing. In the latter
stages of apoptosis, prominent surface protrusions even-
tually separate and form sealed plasma membrane vesicles;
the entire cell is thus reduced to microscopic bodies of
various size and content that are efficiently eliminated by
parenchymal cells and mononuclear phagocytes without
generally triggering an immunologic response. Thus, apo-
ptosis is very distinct from necrosis, as reviewed in Table 1.
Although apoptosis contributes to both tissue develop-
ment and maintenance, it is also clear that abnormal
regulation of this process can be highly deleterious. Apo-
ptosis at an inappropriate time or place, or in excessive or
insufficient amounts, leads to impaired cellular plasticity
and, ultimately, aberrant tissue structure and function. In
this context, excessive apoptotic cell death has been ob-
served in association with cardiovascular, neurological and
immune diseases (2,6–8). In the cardiovascular system,
excessive apoptosis has been associated with the patho-
genesis of heart failure, coronary artery disease, hyperten-
sion and arrhythmogenic right ventricular dysplasia.
Abnormal apoptosis has also been observed in animal
models of ischemia-reperfusion injury, atherosclerosis,
hypoxia, rapid ventricular pacing, pressure-induced cardiac
overload, and myocardial infarction (6,7,9–25) (Table 2).
The development of pharmacologic agents that can inhibit
abnormal cell loss by apoptosis may hold important promise




CCB 5 calcium channel blocker
RR 5 relative risk
TUNEL 5 terminal deoxynucleotide transferase-
mediated dUTP-biotin nick end labeling
Table 1. Apoptosis and Necrosis: Two Distinct Mechanisms of Cell Death
Feature Apoptosis Necrosis
Morphology Loss of cell volume, chromatin condensation, organelles
remain intact
Increased cell volume, nucleus remains intact, loss
of organelle function
Mechanism of action Cascade of genetically regulated events Loss of water and electrolyte balance
Plasma membrane Remains intact Early disruption
DNA cleavage Early, internucleosomal pattern No detectable pattern
Calcium Moderate influx Massive influx
Immune response Phagocytosis Inflammatory response
Table 2. Evidence for Apoptosis in Cardiovascular Disease
Disease Process References
Coronary artery disease Dong et al., 1996 (18); Bochaton-
Piallat et al., 1995 (19); Mallat
et al., 1996 (11); Bjorkerud and
Bjorkerud, 1996 (20)
Hypertension Pollman et al., 1996 (21); Hamet
et al., 1995 (14); Fukuo et al.,




Yao et al., 1996 (24); Narula et
al., 1996 (6)
Ischemic cardiomyopathy Olivetti et al., 1997 (7); Misao et




Mallat et al., 1996 (11)
Conduction disorders James et al., 1996 (17)
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Effects of cell Ca21 modulation on apoptotic cell death.
The ubiquitous role of Ca21 in cell biology would lead one
to suspect that it could have some effect on the complex
process of apoptosis. It is difficult to predict a priori,
however, how changes in any single pathway will ultimately
affect the plethora of Ca21-regulated cell mechanisms. In
fact, both increases and decreases in cellular Ca21 levels
have been shown to promote apoptotic cell death (26–33).
In general, the prevailing view is that elevations in intracel-
lular Ca21 may be one of the key signals leading to the
promotion of apoptosis. Specifically, a link between eleva-
tions in Ca21 levels and apoptosis suggests that this ion can
activate key cation-dependent endonucleases required for
the enzymatic cleavage of nuclear chromatin into small,
discrete fragments (26). An alternative hypothesis is that
elevated Ca21 levels can alter the conformation of nuclear
chromatin in a manner that makes it more accessible to
endonuclease cleavage. However, apoptosis may still occur
even in the absence of internucleosomal DNA (34,35).
A search for the intracellular source of Ca21 that is
involved in the activation of nuclear enzymes during apo-
ptosis has been carefully examined at the cellular level. An
increase in Ca21 levels within the cell nucleus preceding
DNA fragmentation can be attributed to a selective increase
in Ca21 permeability through nuclear pores and/or up-
regulation of Ca21 transport from perinuclear pools (36).
This observation argues that the increase in nuclear Ca21
levels is the result of intracellular Ca21 mobilization, as
opposed to transmembrane influx via voltage-sensitive
Ca21 channels regulated by CCBs (28). A detailed discus-
sion on the intracellular source of Ca21 that may be
involved in apoptosis has been previously covered by Nico-
tera et al. (36).
Complex effects of CCBs on apoptosis. With the advent
of pharmacologic modulators of L-type CCBs, there has
been considerable interest over the past two decades in the
effects of these agents on apoptosis and cell proliferation
(37). Several investigators have hypothesized that CCB
use is associated with an increased risk for tumor develop-
ment by reducing the levels of intracellular Ca21 (38–40),
a potential signal for cellular apoptosis (26,41–43). This
basic assumption, however, is directly contradicted by
the findings of a number of laboratories, demonstrating
that an elevation in cytoplasmic Ca21 is not required for
either the activation of DNA endonucleases or apoptosis
itself (27,30,44,45); apoptosis can be reproducibly initiated
by a decrease in cytyoplasmic Ca21 levels (27–33). Al-
though not fully understood, it has been proposed that low
Ca21 levels prevent cation-mediated charge neutralization
of DNA, resulting in the stimulation of apoptosis. In fact,
chelators of intracellular Ca21 and the calmodulin inhibitor
W-7 have been shown to effectively accelerate the rate of
apoptosis in neutrophils (46). Under cellular conditions
characterized by a deficiency in cytoplasmic Ca21, cells
can be rescued from apoptotic cell death with the use of
Ca21 ionophores or Ca21 channel agonists (31,33). This
lack of an apparent requirement for elevated Ca21 levels
in the cytoplasm during apoptosis suggests that the activa-
tion of cation-sensitive DNA endonucleases may require
only very low levels of Ca21 or may not even be an essential
process (27). This observation could help to rationalize why
CCBs have inconsistent effects on apoptosis (Tables 3
and 4).
A review of the literature indicates that the effects of
CCBs on mechanisms of apoptosis are both Ca21-
dependent and -independent. A number of separate reports
have shown that the addition of CCBs directly promote
apoptosis in both transformed and nontransformed cell
models (29–32,47–55), highlighting the fact that the role
of these agents in this process is difficult to predict (Tables
3 and 4). Inhibition of apoptosis by CCBs has been also
reported, but only in noncancerous systems, and this
effect did not lead to tumor development (Table 4). In
every study on this subject, the antiapoptotic effects of
CCBs were beneficial, as in the case of blocking the
apoptotic destruction of pancreatic beta-cells (50) and
endothelial cells (55,56). In most reports, the CCB concen-
trations necessary to modulate rates of apoptosis (either posi-
tively or negatively) were as much as 1,000-fold higher than
normal pharmacologic levels, as in the case of prostatic glan-
dular cells (41). Although scientifically intriguing, such high
Table 3. CCBs Promote Cellular Apoptosis in Cancer Cells, Leading to a Reduction in Growth
Study Agent Dose Effect on Apoptosis
Kondo et al.,
1995 (29)
Nifedipine 10 mg/ml Combination therapy with cisplatin
induced apoptosis in multidrug-
resistant human glioblastoma cells
Shchepotin et al.,
1994 (48)
Verapamil 50 mg/ml Promoted apoptosis in human




Nimodipine 0.1–1.0 mmol/liter Combination therapy with dantrolene
sodium stimulated apoptosis in a
lymphoma cell line expressing
BCL-2
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levels of CCBs would not be found among patients that use
these agents for the treatment of hypertension and angina.
At supra-pharmacologic CCB levels, one can only spec-
ulate about the mechanism of action by which these agents
interfere with the process of apoptosis. Several studies report
that CCB modulation of apoptosis is entirely independent
of pharmacologic manipulation of Ca21-flux through mem-
brane channels (29,30,51); the ability of CCBs to influence
apoptosis at these elevated levels could be attributed to
interactions with intracellular kinases and membrane trans-
port proteins. Thus, the basic assumption that pharmaco-
logic levels of CCBs inhibit apoptosis by interfering with
cell Ca21 homeostasis and, hence, increase an organism’s
carcinogenic potential is not supported by the scientific
literature. By contrast, substantial support exists for the
opposite to be true: CCBs can promote apoptosis in
transformed cells, especially when administered in combi-
nation with chemotherapeutic agents, resulting in the inhi-
bition of abnormal cell proliferation (29–32,47–55) (Tables
3 and 5).
Activity of CCBs in experimental models of cancer.
Calcium channel blockers bind to membrane-bound, L-type
voltage-sensitive channels in vascular smooth muscle cells at
very low concentrations (low nanomolar levels) in a remark-
ably specific and reversible manner (57–59). At low phar-
macologic levels, CCBs have no apparent effects on other
ion channels or intracellular transduction pathways. Indeed,
if CCBs contribute to tumor development by interfering
with Ca21-mediated apoptosis, then one would expect to
see increased cancer rates with CCB use in tissues enriched
with these Ca21 channels, such as blood vessels or skeletal
muscle. Increases in cancer have not been reported in these
areas, however, even at elevated levels administered over an
extended period of time (60,61).
Contrary to contributing to tumor development, a num-
ber of laboratories have demonstrated that CCBs may be
effective in blocking abnormal cell proliferation when used
either alone or as adjunctive therapy with standard chemo-






Vascular smooth muscle cells in serum-free
media (Leszcynski et al., 1994 [30])
1
Rat thymocytes (Balakumaran et al., 1996 [47]) 1
Cerebellar granule cells (Galli et al., 1995 [32];
Koike et al., 1989 [31])
1
2-methoxyethanol-induced thymic apoptosis
(Balakumaran et al., 1996 [47])
1
IgM-stimulated apoptotic destruction of
pancreatic beta-cells (Juntti-Berggren et al.,
1993 [50])
2
Prostatic involution following removal of
hormonal support (Connor et al., 1988 [52];
Kyprianou et al., 1988 [53])
2
Oxidized LDL-induced apoptotic loss of
cultured endothelial cells (Escargueil-Blanc
et al., 1997 [55])
2
Zinc- and age-induced apoptotic destruction of
cerebellar granule neurons (Mason et al.,
1999 [97])
2
Table 5. CCBs Inhibit Cancer Growth in Cellular and Animal Models
Study Agent Effect on Cancer Growth
Batra et al., 1991 (65) Verapamil Inhibited human prostatic tumor cell growth
Bertrand et al., 1994 (68) Verapamil
Nifedipine
Inhibited cell growth in a pancreatic cell line stimulated by serum or pentagastrin
Chang, 1991 (73) Verapamil Slightly decreased cell number in a pancreatic tumor cell line
Correale et al., 1991 (66) Verapamil Promoted lymphokine-activated killer (LAK) induced reduction in human colon
and breast cancer cell growth
Juraskova and Sladek, 1990 (67) Diltiazem Inhibited lymphosarcoma LS/BL tumor metastasis
Kondo et al., 1995 (29) Nifedipine Inhibited human glioblastoma cell growth when used in combination with
cisplatin in drug-resistant cells
Neckers et al., 1986 (74) Diltiazem Increased the percentage of lymphoblastic leukemia cells in G1 and decreased the
percentage of cells in S or G2-M; associated with a decrease in intracellular
Ca21
Schuller et al., 1991 (70) Verapamil Decreased lung cancer (NCI-H358) cell number at doses as low as 1 nmol/liter.
No effect on cell lines of Clara or alveolar type II origin.
Shchepotin et al., 1994 (48) Verapamil Decreased human primary and metastatic colon adenocarcinoma cell growth
when used in combination with either hyperthemia or 5-fluorouracil
Taylor and Simpson, 1992 (63) Amlodipine
Diltiazem
Verapamil
Inhibited [3H]-thymidine incorporation (cell proliferation) in the breast cancer
cell line, HT-39; amlodipine (0.35 mg/day), diltiazem (3.5 mg/day), or
verapamil (3.5 mg/day) for two weeks inhibited tumor growth after inoculation
of breast cancer cells into athymic nude mice
Uehara et al., 1993 (62) Verapamil Inhibited hepatocarcinogenesis induced by N-nitrosomorpholine in rats
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therapeutic agents (29,48,62–74), as shown in Table 5. A
summary of the established mechanisms by which CCBs
may interfere with carcinogenesis is reviewed in Table 6. In
many cases, the beneficial mechanism of action for these
agents, especially in drug-resistant tumors, appears to be
entirely independent of Ca21 channel modulation (29,75–77).
The lipophilic CCB verapamil, in particular, has been shown
to be effective in improving the efficacy of agents used to treat
certain cancers as a result of interfering with the function of the
membrane-bound MDR1 protein (78–80). In addition, the
antitumor activity of the dihydropyridine CCB nifedipine was
demonstrated in human glioblastoma cells. When used in
combination with cisplatin, nifedipine inhibited tumor growth
by inducing apoptosis (29).
The benefit of CCBs in models of cancer is also due to
the fact that the Ca21 ion itself has an important role as a
mitogenic signal that stimulates abnormal cell growth
(63,64,70,72,81,82). For this reason, CCBs alone can be
effective in the treatment of certain types of tumors by
maintaining normal Ca21 homeostasis. In a breast cancer
system, for example, it was reported that representative
CCBs (diltiazem, amlodipine, and verapamil) were very
effective in blocking the growth of human breast cancer
cells in a concentration-dependent manner (63). In parallel
animal studies, CCBs dramatically inhibited tumor
growth as compared to controls, by reducing excessive cell
Ca21 levels linked to abnormal cell growth (63). As these
effects were observed using pharmacologic levels of the
drugs, the authors of that study suggest that CCBs may
be useful in the treatment of certain Ca21-dependent
neoplasias, such as breast cancer (63). Moreover, CCBs
have been shown to be effective in blocking proliferation of
nontransformed cell lines following mitogenic stimulation,
an observation that also has therapeutic implications in the
pathogenesis of hypertension and atherosclerosis (83–86).
Finally, the antioxidant activity of certain CCBs may
also interfere with abnormal cell proliferation mechanisms
(87–92). Well-known antioxidants such as vitamin E have
been shown to be successful inhibitors of cancer growth,
presumably by interfering with oxy-radical-mediated cell
damage (93–96). Similarly, electron-rich dihydropyridine
CCBs are very effective as “chain-breaking” antioxidants,
especially analogs that have high affinity for the cell mem-
brane (97).
Beyond cellular systems of investigation, the effects of
CCBs on tumor development have been extensively and
systematically evaluated in well-defined animal models,
as required by government regulatory agencies. The whole
animal represents a fully integrated system in which to
evaluate the potentially complex and multifactorial effects
of these compounds on cancer development. In addition to
reproducing human physiologic processes, animal studies
also provide the opportunity to evaluate CCB activity at
supra-pharmacologic doses. Results of these studies
demonstrated that CCB used neither increased rates of
mutagenesis nor affected the frequency of tumor de-
velopment in the animals, even when administered during
the entire life span (60,61). Animal genotoxicity animal
studies are consistent with large observational studies that
have failed to demonstrate a consistent increase in overall
risk for cancer among hypertensive patients using CCBs
(98–115).
CCB effects on cancer incidence in human studies. A
retrospective analysis by Pahor et al. (116) raised concern
about a potential link between CCB use and an increased
susceptibility to cancer. Although the authors of that study
acknowledged methodologic limitations with the study,
their results have nonetheless raised significant concern in
the medical community and the general public as a result of
widespread media reports. This concern has stimulated a
careful analysis of the clinical data related to this question,
as reviewed in Table 7. The overwhelming majority of
observational analyses failed to find an increased risk for
cancer in association with CCB use (98–112,114,115). An
exception is the report by Pahor and colleagues (116) that
compared, in retrospective fashion, cancer incidence in 202
elderly patients on CCBs only (primarily short-acting
agents) to 424 subjects on beta-blockers only. The reason
Table 6. Effects of CCBs on Mechanisms of Carcinogenesis
Process Effects of CCBs Role of Ca21 References
Cell proliferation Beneficial: CCBs inhibit cell proliferation associated
with hypercalcemia and mitogenic stimulation at
pharmacologic levels
Ca21-dependent Taylor and Simpson, 1992 (63); Batra
et al., 1991 (65); Tulenko et al., 1997
(86); Yang et al., 1993 (83)
Free radicals Beneficial: Highly lipophilic CCBs inhibit free
radical-induced damage to cellular components at
pharmacologic levels
Ca21-independent Mak and Weglicki, 1990 (88); Ondrias
et al., 1989 (89); Mak et al., 1992
(87); Mason et al., 1999 (97)
Apoptosis Beneficial: CCBs promote apoptosis as adjunctive
therapy in drug-resistant tumors by interfering
with the MDR1 transport system at high levels
Ca21-independent Kondo et al., 1995 (29); Timcheva et al.,
1996 (80); Shamash et al., 1994 (49);
Cornwell et al., 1987 (77)
Mutagenesis Neutral: No effect (positive or negative) in extensive
animal mutagenicity assays, even at supra-
pharmacologic levels
NA Anundi, 1997 (61); Ahr et al., 1997 (60)
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for this anomalous finding may be due to several method-
ologic limitations (106,117–119), including:
c Few cases of cancer (61 total) occurred in the Pahor et al.
case-control study
c An accurate measurement of actual drug usage was
unlikely as exposure was assessed only at a single time
point at study baseline, 6 to 10 years before cancer was
diagnosed
c Multiple differences in the health characteristics of the
CCB users versus nonusers likely led to selection bias
(e.g., CCB users had more hospital admissions and more
concomitant disease).
By contrast, a much larger study by Jick et al. (106)
demonstrated no correlation between CCB dose or time of
exposure with measured changes in cancer incidence among
patients, including elderly subjects. These clinical findings
serve to undermine a causative role for CCBs in cancer
development. Similar in design to the study by Pahor et al.
(116), Jick et al. (106) compared hypertensive patients who
were using CCBs only (n 5 751) to those on either
beta-blockers (n 5 938) or ACE inhibitors (n 5 507).
However, the Jick et al. study had several methodologic
advantages over the previous analysis, including a much
larger number of cancer cases (n 5 446) and multiple
study-drug exposure assessments, beginning at least four
years prior to any diagnosis of cancer. Using a nested
case-control analysis, the relative risk (RR) estimate for
users of the highest doses of CCBs for the longest period in
the study was low, 0.70 (95% CI: 0.24 to 2.1) (106). Overall,
the RR of incidence for CCBs was inversely related to time
of drug use; hypertensive patients who used CCBs for the
longest time period in the study (at least four years) had a
lower risk for cancer than did those taking the drug for less
than one year (106). The lack of any correlation between
drug use or time of exposure and carcinogenic potential
argues persuasively against a cause-and-effect role for CCBs
in cancer. In addition to an analysis of overall cancer
incidence, the effects of CCBs on site-specific cancers, such
as breast or prostate cancer, have also been carefully as-
sessed, and the majority of these studies failed to support a
causal relationship (Table 8).
Any increase in rates of cancer associated with the use of
antihypertensive medications may be attributed to the ef-
fects of hypertension, as opposed to any specific pharmaco-
logic therapy (119,120). In support of this hypothesis, it is
has been reported that other widely used antihypertensive
medications, including beta-blockers and diuretics, have
been linked to an increased risk for malignancy (114,121–
130) (Table 9). Curiously, these studies did not attract
nearly the same attention by the medical community as did
the small number of negative reports related to CCBs. In
general, changes in cancer rates associated with the use of
these other antihypertensive agents were attributed to
chance, and therefore dismissed. Nonetheless, these find-
ings suggest that further study is needed into the biologic
contribution of hypertension itself to mechanisms of cancer
development (119,120).
Conclusions. A biologic hypothesis that links CCB use to
an increased risk for cancer as a result of interfering with
apoptosis is not supported by the scientific literature. Over
the past two decades, the role of Ca21 in cellular apoptosis
has been carefully investigated. Studies have shown that the
effect of Ca21 on apoptosis is complex: both increases and
decreases in the levels of this ubiquitous ion have been
associated with increases in apoptosis. With the develop-
ment of pharmacologic modulators of L-type calcium chan-
nel modulators, intensive investigations have been pursued
concerning their specific effects on apoptosis. Results of
these analyses have been highly variable, depending on the
experimental model and dose of drug utilized. Most studies
have shown that an effect (either positive or negative) of
these agents on apoptosis requires drug doses in the supra-
pharmacologic range, and are therefore not relevant to the
clinical use of these compounds. Safety of these agents with
respect to cancer incidence has also been demonstrated in
extensive preclinical animal studies and large clinical anal-
yses. Thus, a comprehensive assessment of the cellular,
animal, and human evidence indicates that use of CCBs
Table 7. Effect of CCB Use on Human Cancer Incidence
Study Study Design
CCB Cancer
Cases RR (95% CI)
Rosenberg et al., 1998 (99) Case control 481 1.1 (0.9–1.3)
Michels et al., 1998 (101) Cohort 122 1.02 (0.83–1.26)
Jick et al., 1997 (106) Case control 178 1.17 (0.98–1.63)
Pahor et al., 1996 (116) Cohort 47 1.72 (1.27–2.34)
Hole et al., 1998 (114) Cohort 134 1.02 (0.82–1.27)
Braun et al., 1998 (103) Cohort 129 1.07 (0.83–1.37)
Messerli and Grossman, 1998 (115) Pooled clinical trials 97 0.78 (NA)
Jonas et al., 1998 (105) Cohort 22 1.06 (0.52–2.18)
Trenkwalder et al., 1998 (109) Cohort 15 1.12 (0.7–1.8)
Dong et al., 1997 (112) Pooled clinical trials 10 0.73 (0.39–1.39)
Olsen et al., 1997 (98) Registry (cohort) 411 1.00 (0.9–1.1)
1862 Mason JACC Vol. 34, No. 7, 1999
Apoptosis, Calcium Channel Modulation, and Cancer December 1999:1857–66
would not be expected to increase the risk for cancer
development by interfering with apoptosis. The World
Health Organization (WHO) and the International Society
of Hypertension reached a similar conclusion (131). A
liaison committee from these groups stated, “The available
evidence from observational studies does not provide good
evidence of an adverse effect of calcium antagonists on
cancer risk” (WHO 1997) (131).
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